Results 221 to 230 of about 178,517 (322)

Retraction: Bruton's tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice. [PDF]

Front Immunol
Frontiers Editorial Office.
europepmc   +1 more source

A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis. [PDF]

J Clin Invest, 2023
Suresh RV, Dunnam C, Vaidya D, Wood RA, Bochner BS, MacGlashan DW, Dispenza MC.   +6 more
europepmc   +1 more source

Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma. [PDF]

J Oncol Pharm Pract
Lu J, Do B, Primeaux B, Primeaux B.
europepmc   +1 more source

Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder. [PDF]

J Neuroinflammation, 2023
Liu Y, Huang Z, Zhang TX, Han B, Yang G, Jia D, Yang L, Liu Q, Lau AYL, Paul F, Verkhratsky A, Shi FD, Zhang C.   +12 more
europepmc   +1 more source

Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. [PDF]

Cancer Cell
Phelan JD, Scheich S, Choi J, Wright GW, Häupl B, Young RM, Rieke SA, Pape M, Ji Y, Urlaub H, Bolomsky A, Doebele C, Zindel A, Wotapek T, Kasbekar M, Collinge B, Huang DW, Coulibaly ZA, Morris VM, Zhuang X, Enssle JC, Yu X, Xu W, Yang Y, Zhao H, Wang Z, Tran AD, Shoemaker CJ, Shevchenko G, Hodson DJ, Shaffer AL, Staudt LM, Oellerich T.   +32 more
europepmc   +1 more source

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

, 2023
Xiaoli Wang, Andrew Davis, Xiaoping Su, Muharrem Müftüoǧlu, Cecile M. Krejsa, John Mascarenhas, Michael Andreeff, Ronald Hoffman   +7 more
openalex   +1 more source

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]

Cancer Immunol Immunother
Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, Siddiqui A, Pracha SH, Roth P, Iwenofu OH, Oghumu S.   +10 more
europepmc   +1 more source

Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages

, 2013
Karin Strijbis, Fikadu Tafesse, Gregory D. Fairn, Martin D. Witte, Stephanie K. Dougan, Nicki Watson, Eric Spooner, Alexandre Esteban, Valmik K. Vyas, Gerald R. Fink, Sergio Grinstein, Hidde L. Ploegh   +11 more
openalex   +2 more sources

Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL). [PDF]

Cancer Chemother Pharmacol
Ouerdani A, Valenzuela B, Treijtel N, Haddish-Berhane N, Desphande S, Srinivasan S, Smith E, Perez Ruixo JJ.   +7 more
europepmc   +1 more source

Bruton's Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae. [PDF]

J Innate Immun, 2023
Liu Z, De Porto APNA, De Beer R, Roelofs JJTH, De Boer OJ, Florquin S, Van't Veer C, Hendriks RW, Van der Poll T, De Vos AF.   +9 more
europepmc   +1 more source